Increased cerebrospinal fluid adenosine 5'-triphosphate in patients with amyotrophic lateral sclerosis

BMC Neurology

Table 1 Demographic of patients with iNPH and ALS

	iNPH (n = 10)	Mild group (n = 37)	Severe group (n = 11)	P value
Age	71.1 ± 3.8	63.0 ± 13.3	69.5 ± 8.8	0.09
Male (%)	5 (50.0)	25 (67.6)	7 (63.6)	0.62
MRC sum score	59.3 ± 1.3	56.7 ± 3.0	44.2 ± 4.7	< 0.0001 *
BMI	23.4 ± 2.4	21.2 ± 3.0	21.1 ± 2.6	0.10
ALSFRS-R		42.4 ± 2.8	37.9 ± 5.7	< 0.01 *
Disease duration (onset to CSF sampling, months)		10.5 ± 8.4	15.8 ± 11.5	0.016 *
Disease duration ^a (onset to death or ventilator, months)		28.9 ± 18.0	24.3 ± 9.0	0.971
Residual time (months) ^a		18.2 ± 15.3	11.6 ± 5.5	0.309

Data are presented as mean ± SD or number (%), * indicates p < 0.05 (wilcoxon test)
Mild group; MRC sum scores > 49, Severe group MRC sum scores ≤ 48
Residual time; duration to use of a ventilator or death after CSF sampling
n = number of samples, ALSFRS-R ALS functional rating scale-revised, iNPH Idiopathic normal pressure hydrocephalus, BMI Body mass index,
^a When comparing disease duration (onset to death or ventilator) or residual time, the mild group included 33 samples and severe group included 7 samples because remaining patients were alive without needing a ventilator

ISSN: 1471-2377